FINWIRES · TerminalLIVE
FINWIRES

SGX:O6Z

3 stories mentioning SGX:O6ZUpdated 26d ago

Every FINWIRES story that references SGX:O6Z, newest first.

Asia Markets

Singapore Shares Gain More Than 1% as AI Boom Extends; MetaOptics Soars 11%

Singapore shares extended gains on Wednesday, soaring more than 1% at the close, despite mixed results across the region as chipmakers influencing investor sentiment.The Straits Times Index (STI), a key benchmark for the Singapore Exchange, ranged between 5,483.04 and 5,595.42 throughout the day. It ended the session at 5,595.42, up 68.70 points or 1.2% compared to Tuesday's close.On the corporate front, shares of MetaOptics (SGX:9MT) surged over 11% at the close as it agreed to deploy its metalens direct laser writer system at the University of Arizona's Center of Semiconductor Manufacturing.First Sponsor (SGX:ADN) expects to recognize an impairment charge of roughly SG$36.7 million in its first-half financial statements following an adverse ruling by a court in Dongguan, China.Meanwhile, Lonza's (SGX:O6Z) attributable profit to equity holders during the first half of the year rose to 591 million Swiss francs from 426 million francs a year earlier.

^STISGX:9MTSGX:ADNSGX:O6Z
Asia

Lonza Books Higher Attributable Profit in H1

Lonza's (SGX:O6Z) attributable profit to equity holders during the first half of the year rose to 591 million Swiss francs from 426 million francs a year earlier, according to a Wednesday filing with the Singapore Exchange.Earnings per share rose to 8.16 francs compared with 5.67 francs in the year-ago period.The Swiss pharmaceutical company's sales rose 11% year over year to 3.37 billion francs from 3.03 billion francs.

SGX:O6Z
Asia

Lonza Group Delivers Strong Performance in Q1

Lonza Group (SGX:O6Z) delivered strong contract development and manufacturing organization (CDMO) growth during the first quarter of the year, according to a Friday filing with the Singapore Exchange.The Swiss pharmaceutical company expects stronger sales in the first half of 2026 compared to the second half, backed by a lower prior-year base and planned site shutdowns.The momentum in Q1 was led by strong contributions from the integrated biologics segment and improvement from the specialized modalities segment.Lonza projects sales growth of 11% to 12% at constant exchange rates for the full year 2026.Over the medium term, the dual-listed group targets average sales growth in the low teens at constant exchange rates.

SGX:O6Z

Track with the FINWIRES app suite